Md Saiful Islam Khan Heavily pretreated multiple myeloma patients treated with Pfizer's ( NYSE: PFE ) Elrexfio (elranatamab) demonstrated a median survival of 24.6 months in a phase 2 trial. After more than two years of follow-up in the MagnetisMM-3 trial, the overall response rate for treated patients was 61.
0%, with responses becoming more significant over time. Median progression-free survival ( PFS ) was 17.2 months.
Elrexfio is approved for patients who have received at least four prior treatments. More on Pfizer Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Revenues FDA recommends KP.
2 strain be used in updated COVID-19 shots Sarepta gains after Pfizer's late-stage setback for Duchenne therapy.
